24Jan/14

European Setback For Novartis Heart Failure Drug – Forbes


Economic Times

European Setback For Novartis Heart Failure Drug
Forbes
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended against giving market approval to serelaxin (Reasanz) for the treatment of acute heart failure. The recommendation is based largely on the 
Novartis still sees heart failure blockbuster after EU blowEconomic Times
UPDATE 2-Novartis still sees heart failure blockbuster after EU blowReuters
Novartis to request re-examination of serelaxin (RLX030) in acute heart FiercePharma
Reuters India –Businessweek
all 44 news articles »
24Jan/14

Channel swim death of Susan Taylor due to heart failure, inquest told – Leicester Mercury


Leicester Mercury

Channel swim death of Susan Taylor due to heart failure, inquest told
Leicester Mercury
The desperate attempts to save the life of a “wonderful and caring” woman who got into difficulty as she neared the end of a cross-Channel swim have been revealed at her inquest. Susan Taylor, of Barwell, was a mile from the French shore when she began 

and more »

24Jan/14

Novartis still sees heart failure blockbuster after EU blow – Economic Times


Economic Times

Novartis still sees heart failure blockbuster after EU blow
Economic Times
“Novartis announced today it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030, or serelaxin,” the Basel-based drugmaker said in a statement.
Novartis Denied EU’s Nod for Heart-Failure Drug Serelaxin (3)Businessweek
UPDATE 2-Novartis still sees heart failure blockbuster after EU blowReuters
Novartis to request re-examination of serelaxin (RLX030) in acute heart FiercePharma
Reuters India –RTT News
all 26 news articles »